Business Summary
|
Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical treatments for under-served markets in oncology and infectious diseases. The Company’s product candidates include two oncology product candidates based on targeted therapies: TLN-4601, a first-in-class small molecule and TLN-232, a peptide, both with potential efficacy in multiple oncology indications, as well as Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections. In May 2008, the Company received authorization from the Therapeutic Products Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-4601 as a second line monotherapy treatment for patients with GBM, an advanced form of brain cancer.
| | (Source: ARS)
|
|
|
